Abstract:Jinghua Sun, 1, &ast Ge Sun, 1, &ast KeMou Lu, 1 Lingling Xu, 1 XiaoNa Qu, 1 Ye Cheng, 1 Evenki Pan, 2 Peng Yang, 2 Tingting Wu, 2 Yang Zhang, 1 HongMei He 1 1 The Second Affiliated Hospital of Dalian Medical University, Dalian, People's Republic of China; 2 Nanjing Geneseeq Technology Inc., Nanjing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yang Zhang; HongMei He, The Second Affiliated Hospital of Dalian Medical University, Dalian, No. 467, Zhongshan Road, Shahekou District, Dalian, People's Republic of China, Email ; For advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor ( EGFR ) mutations, EGFR tyrosine kinase inhibitors (TKIs) have been approved as the standard therapy and shown clinical benefits. However, the emergence of drug resistance is inevitable. Tumor heterogeneity was often observed by imaging method to evaluate the progression of primary and metastatic lesions. Tissue biopsy was also unlikely to accurately capture the complete genomic landscape from a single tissue sample. Recently, genomic characterization of circulating tumor DNA (ctDNA) offer an opportunity to reveal the clonal dynamics throughout the course of a patient's illness and provide comprehensive genomic landscape of tumors to assess tumor heterogeneity. Here, we reported a lung adenocarcinoma (LADC) with EGFR mutations who was treated with sequential EGFR TKIs. The CT image of the patient's different lesions suggested that dynamic change of tumor heterogeneity had occurred. Targeted next-generation sequencing (NGS) analysis of ctDNA revealed dynamic changes of mutational profiles between the primary and metastatic tumors to discover tumor evolution to guide treatment decision-making. Keywords: tumor heterogeneity, circulating tumor DNA, ctDNA, resistance mutation, next-generation sequencing, NGS In Asian non-small cell lung cancer (NSCLC) patients, somatic activating mutations in the epidermal growth factor receptor ( EGFR ) such as point mutation L858R within exon 21 and short in-frame deletions within exon 19 are the most common oncogenic driver mutation. 1 With the development of targeted therapy and next-generation sequencing (NGS) technology, the therapeutic strategies for lung cancer have evolved into a new era of genomics-guided precision medicine. These EGFR -targeted tyrosine kinase inhibitors (TKIs) have shown improved tumor response and progression-free survival (PFS) outcome in EGFR -mutated NSCLC. 2 Although EGFR T790M mutation have been confirmed as first- and second-generation EGFR -TKIs resistance mutations, a third-generation EGFR -TKI of osimertinib has shown efficacy in counteracting the growth of EGFR T790M mutant tumors. 3 Although osimertinib has demonstrated high clinical efficacy, developing resistance is also inevitable. The biggest hurdle for the successful treatment of cancer is the tumor heterogeneity, which can take different forms of intratumor, intermetastatic or intrametastatic heterogeneity within an individual patient. 4 Computed tomography (CT) remains the initial imaging method for clinical staging of lung cancer, evaluating the change of primary and metastatic lesions. Recently, gene sequencing of circulating tumor DNA (ctDNA) from a liquid biopsy or blood sample can provide comprehensive genetic information of all cancerous lesions (primary and metastases), which overcomes spatial and temporal heterogeneity of a single-tumor biopsy sample, as well as facilitates dynamic tracking of genomic evolution for formatting a treatment strategy. 5 We herein report a case of lung adenocarcinoma (LADC) with EGFR mutations, whose different tumor lesions exhibited different response to the EGFR -TKIs. The NGS analysis of ctDNA revealed dynamic changes of mutational profiles between the primary and metastatic tumors. A 44-year-old female was diagnosed with stage IV LADC (cT2bN2M1c) in the right lung center with lymph nodes metastases in February 2017. Positron emission tomography-computed tomography (PET-CT) scan indicated a 14×9 mm density mass in the upper lobe of right lung and a 23×7 mm density mass in the right hilum, respectively (Figure 1). Immunohistochemistry (IHC) staining of tumor biopsy showed positive for LADC markers thyroid transcription factor-1 (TTF-1) and Napsin-A, but negative for lung squamous cell carcinoma (LSCC) markers P40 and P63. NGS demonstrated EGFR L858R with a mutation allelic frequency (MAF) of 0.5%, in plasma and 19.7% in tumor tissue of the upp -Abstract Truncated-

Adenocarcinoma of the Lung with EGFR Gene Mutation and Subsequent Resistance Mechanisms Exploration: Case Report.

Poor response to gefitinib in lung adenocarcinoma with concomitant epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement

Concurrent Epidermal Growth Factor Receptor T790M Secondary Mutation and Epithelial‐mesenchymal Transition in a Lung Adenocarcinoma Patient with EGFR‐TKI Drug Resistance

A case of lung adenocarcinoma harboring exon 19 EGFR deletion and EML4-ALK fusion gene

A Case of Lung Adenocarcinoma with a Concurrent EGFR Mutation and ALK Rearrangement: A Case Report and Literature Review

A Novel Acquired EGFR-SEPT14 Fusion Confers Differential Drug Resistance to EGFR Inhibitors in Lung Adenocarcinoma.

Advanced Lung Adenocarcinoma with EGFR 19-del Mutation Transformed into SCC after EGFR-tyrosine Kinase inhibitors Treatment: A Case report

Lung Adenocarcinoma Harboring Triple Rare EGFR Exon 18 Mutations Rapidly Developed Resistance to Multiple Therapies

Lung adenocarcinoma harboring L858R and T790M mutations in epidermal growth factor receptor, with poor response to gefitinib: A case report.

Tumor Heterogeneity and Drug Resistance Mutations Using ctDNA in Metastatic EGFR Mutation-Positive Lung Adenocarcinoma: A Case Report

A Case Report of EGFR Mutant Lung Adenocarcinoma That Acquired Resistance to EGFR-tyrosine Kinase Inhibitors with T790M Mutation and Epithelial-to-mesenchymal Transition

L858r-Positive Lung Adenocarcinoma with Kras G12v, Egfr T790m and Egfr L858r Mutations: A Case Report

EP1.14-46 the KIF5B-RET Fusion As a Novel Mechanism of Acquired EGFR Tyrosine Kinase Inhibitor Resistance in Lung Adenocarcinoma

Tyrosine kinase inhibitor acquired resistance mechanism alternates between EGFR and ALK in a lung adenocarcinoma patient

Acquired Resistance of Lung Adenocarcinoma to EGFR-tyrosine Kinase Inhibitors Gefitinib and Erlotinib

Case report: Concomitant EGFR mutation and ALK rearrangement in non-small cell lung cancer

Resistance to Epithelial Growth Factor Receptor Tyrosine Kinase Inhibitors in a Patient with Transformation from Lung Adenocarcinoma to Small Cell Lung Cancer: A Case Report

EGFR L747P Mutation in One Lung Adenocarcinoma Patient Responded to Afatinib Treatment: a Case Report

P3.01-104 EGFR-RAD51 Fusion Variant in Lung Adenocarcinoma and Response to Erlotinib: A Case Report

Case Report: Heterogeneity of Resistance Mechanisms in Different Lesions Co-Mediate Acquired Resistance to First-Line Icotinib in EGFR Mutant Non-Small Cell Lung Cancer

P3.CR-09 MET-UBE2H fusion as a novel mechanism of acquired EGFR resistance in lung adenocarcinoma" with "MET fusion as a novel mechanism of acquired EGFR resistance in lung adenocarcinoma